Structure-based design and characterization of Parkin-activating mutations.

Area of Science:

• Biochemistry
• Neuroscience
• Genetics

Background:

• Parkinson's disease is often caused by mutations in the Parkin gene, which encodes a key protein in mitochondrial quality control.
• Parkin protein's E3 ligase activity is essential but is regulated by an inactive conformation, making its activation a therapeutic target.

Purpose of the Study:

• To explore targeted activation of the Parkin protein by identifying specific regions and mutations that enhance its ligase activity.
• To investigate the structural basis for Parkin activation and its functional consequences in cellular models.

Main Methods:

• Employed a structure-based approach to rationally design mutations in human and rat Parkin.
• Tested 31 mutations across interdomain interfaces, focusing on RING0:RING2 and REP:RING1 interfaces.
• Assessed mutant activity, thermal stability, and mitophagy rescue in cell-based assays.

Main Results:

• Identified 11 novel activating mutations in Parkin, primarily located at the RING0:RING2 or REP:RING1 interfaces.
• Observed a correlation between increased Parkin activity and reduced thermal stability of the mutants.
• Demonstrated that three specific mutations (V393D, A401D, W403A) rescued Parkin's mitophagy defect in cellular studies.

Conclusions:

• The study provides insights into the structural mechanisms of Parkin activation by targeting interdomain interfaces.
• Small molecules designed to destabilize these interfaces could offer a therapeutic approach for Parkinson's disease.
• These findings advance the development of targeted therapies for patients with specific Parkin mutations.